The estimated Net Worth of Dennis Karl Huang is at least $9.4 Million dollars as of 1 March 2023. Mr. Huang owns over 389 units of Ultragenyx Pharmaceutical stock worth over $4,242,438 and over the last 10 years he sold RARE stock worth over $914,533. In addition, he makes $4,242,540 as Chief Technical Operations Officer and Executive Vice President at Ultragenyx Pharmaceutical.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Huang RARE stock SEC Form 4 insiders trading
Dennis has made over 6 trades of the Ultragenyx Pharmaceutical stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 389 units of RARE stock worth $17,758 on 1 March 2023.
The largest trade he's ever made was selling 4,255 units of Ultragenyx Pharmaceutical stock on 1 March 2021 worth over $587,956. On average, Dennis trades about 316 units every 31 days since 2015. As of 1 March 2023 he still owns at least 75,314 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Mr. Huang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dennis Huang biography
Dennis Karl Huang serves as Chief Technical Operations Officer, Executive Vice President of the Company. Prior to Ultragenyx, Mr. Huang served as Senior Vice President of Manufacturing and Supply Chain at InterMune, Inc., a biotechnology company, from August 2013 to March 2015. Prior to InterMune, Mr. Huang served as Vice President of Biologic Manufacturing and Development at Allergan, Inc., a global pharmaceutical company, from May 2006 to August 2013. Mr. Huang currently serves on the board of directors of CytoDel, Inc., a private biopharmaceutical company. Mr. Huang holds a B.A. in Chemistry from Knox College in Galesburg, Illinois.
What is the salary of Dennis Huang?
As the Chief Technical Operations Officer and Executive Vice President of Ultragenyx Pharmaceutical, the total compensation of Dennis Huang at Ultragenyx Pharmaceutical is $4,242,540. There are 1 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
How old is Dennis Huang?
Dennis Huang is 55, he's been the Chief Technical Operations Officer and Executive Vice President of Ultragenyx Pharmaceutical since 2016. There are 16 older and 7 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
What's Dennis Huang's mailing address?
Dennis's mailing address filed with the SEC is 60 Leveroni Ct, Novato, CA 94949, USA.
Insiders trading at Ultragenyx Pharmaceutical
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr, and Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
What does Ultragenyx Pharmaceutical do?
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
What does Ultragenyx Pharmaceutical's logo look like?
Complete history of Mr. Huang stock trades at Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical executives and stock owners
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include:
-
Emil Kakkis,
President, Chief Executive Officer, Director -
Dennis Huang,
Chief Technical Operations Officer, Executive Vice President -
John Pinion,
Chief Quality Officer and Executive Vice President of Translational Sciences -
Camille Bedrosian,
Chief Medical Officer and Executive Vice President -
Thomas Kassberg,
Chief Business Officer, Executive Vice President -
Karah Parschauer,
Executive Vice President, General Counsel -
Dr. Emil D. Kakkis M.D., Ph.D.,
Pres, CEO & Director -
Shehnaaz Suliman,
Independent Director -
Dr. Camille L. Bedrosian M.D.,
Chief Medical Officer & Exec. VP -
Erik Harris,
Exec. VP & Chief Commercial Officer -
John Richard Pinion II,
Chief Quality Operations Officer & Exec. VP of Translational Sciences -
Daniel Welch,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
William Aliski,
Independent Director -
Michael Narachi,
Independent Director -
Lars Ekman,
Independent Director -
Clay Siegall,
Independent Director -
Deborah Dunsire,
Independent Director -
Mardi C. Dier,
Exec. VP & CFO -
Mardi Dier,
Chief Financial Officer, Executive Vice President -
Ernie Meyer,
Chief Human Resource Officer, Executive Vice President -
Erik Harris,
Executive Vice President and Chief Commercial Officer -
Ernie W. Meyer,
Chief HR Officer & Exec. VP -
Karah Herdman Parschauer J.D.,
Gen. Counsel & Exec. VP -
Danielle Keatley,
Sr. Director of Investor Relations & Corp. Communications -
Dennis Karl Huang,
Chief Technical Operations Officer & Exec. VP -
Theodore A. Huizenga,
VP, Corp. Controller & Principal Accounting Officer -
Sunil Agarwal,
Chief Medical Officer -
Jayson Donald Alexander Dallas,
See Remarks -
Wladimir Hogenhuis,
Chief Operating Officer -
Llc Fmr,
10% owner -
Marten Steen,
Director -
Group Holdings (Sbs) Adviso...,
-
Eran Nadav,
Director -
Amrit Ray,
-
Shalini Sharp,
EVP, Finance -
Corazon (Corsee) D. Sanders,
-
Theodore Alan Huizenga,
SVP, Chief Accounting Officer -
Eric Crombez,
EVP and Chief Medical Officer -
Howard Horn,
Chief Financial Officer